Investigating the effects of long-term pilocarpine use for presbyopia treatment on posterior ocular structures

The University of Auckland0 个研究点目标入组 21 人开始时间: 2024年4月2日最近更新: 2024年4月8日

适应症

试验速览

暂无简介。

•Healthy adults who only wear optical correction (glasses and/or contact lenses) for presbyopia correction, and are willing and able to provide written informed consent for study participation.

•- Ametropia, defined as over 0.50 Dioptres of myopic or hyperopic mean sphere refractive error
•- History of ocular disease, injury, or surgery that affects or has the potential to affect the participant’s vision over the study duration
•- Any history of ocular or systemic conditions that are contraindications for receiving pilocarpine eye drops as a medical therapy that would put participants' safety at risk.
•- A personal or family history of epilepsy or seizures, neurological disorders/ disease, or serious head injury and/or skull fracture, as these may affect performance in MRI procedures involving viewing flickering visual patterns (e.g. epilepsy) and/or lying still for an extended period of time (e.g. claustrophobia)
•- Having metal implants (e.g. a cardiac pacemaker) or other contraindications that would put the safety of the participant at risk when undergoing an MRI scan
•- Pregnant or breastfeeding women, as safety of pilocarpine eye drops has not been established for use in pregnancy and lactation. For this reason, participants who become pregnant during the study will also not be able to continue participation.

发起方